Analyst Price Targets — BDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 17, 2026 11:40 am | Jason Bednar | Piper Sandler | $159.00 | $154.82 | TheFly | Becton Dickinson price target lowered to $159 from $170 at Piper Sandler |
| April 14, 2026 11:17 am | — | RBC Capital | $175.00 | $155.43 | TheFly | Becton Dickinson price target lowered to $175 from $195 at RBC Capital |
| April 10, 2026 4:09 am | David Roman | Goldman Sachs | $167.00 | $154.42 | TheFly | Becton Dickinson resumed with a Neutral at Goldman Sachs |
| February 10, 2026 1:54 pm | Shagun Singh | RBC Capital | $172.00 | $170.14 | TheFly | Becton Dickinson price target lowered to $172 from $210 at RBC Capital |
| February 10, 2026 12:15 pm | Matt Miksic | Barclays | $202.00 | $207.39 | TheFly | Becton Dickinson reinstated with an Overweight at Barclays |
| February 10, 2026 11:28 am | — | Piper Sandler | $170.00 | $207.39 | TheFly | Becton Dickinson price target lowered to $170 from $205 at Piper Sandler |
| January 28, 2026 11:51 am | Jason Bednar | Piper Sandler | $161.16 | $159.91 | TheFly | Becton Dickinson price target raised to $205 from $190 at Piper Sandler |
| January 7, 2026 12:34 pm | — | Stifel Nicolaus | $169.03 | $161.45 | TheFly | Becton Dickinson price target raised to $215 from $210 at Stifel |
| December 17, 2025 12:23 pm | — | RBC Capital | $165.09 | $154.39 | TheFly | Becton Dickinson price target raised to $210 from $202 at RBC Capital |
| December 2, 2025 11:37 am | Patrick Wood | Morgan Stanley | $165.09 | $150.80 | TheFly | Becton Dickinson price target raised to $210 from $197 at Morgan Stanley |
Latest News for BDX
Here, we highlight three dental supplies stocks, CAH, COO and BDX, which are well positioned to generate wealth for investors amid macro uncertainty.
Becton, Dickinson is rated a 'BUY' under $160/share, driven by attractive fundamentals and a conservative valuation approach. Despite the recent spin-off of its high-margin bioscience segment, BDX retains core medtech operations with solid profitability and robust cash flow generation. I see BDX's current 13x P/E as undervalued, with a fair value target of $215/share by 2028E and an annualized return above 15% at…
Becton, Dickinson has been increasing its dividend for more than 50 consecutive years. While diversified, much of its revenue comes from recurring sales of medical supplies.
Becton, Dickinson has become oversold following a spinoff, but analysts call for a growth rebound starting next year. PepsiCo is another oversold Dividend King, trading at multiyear lows, with a historically high forward dividend yield.
This trio has typically outpaced the S&P 500 in economic downturns. The three are healthcare leaders with plenty of size and diversity.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.